Anti-payload Antibodies

Highly Potent Tool for ADCs Pharmacokinetic (PK) Analysis!

Anti-DXD mAb

Exatecan derivative for ADC (DXD) is an inhibitor targeting DNA topoisomerase I, belonging to the camptothecin (CPT) class of compounds. DNA topoisomerase I inhibitors currently stand as the most promising ADC payloads, causing DNA damage and cell apoptosis by cleaving single-strand DNA and suppressing the topoisomerase repair mechanism. The new generation DXD-ADC employs DXD as a drug carrier (payload) that effectively determines DXD stability and release efficiency, applicable in plasma/serum pharmacokinetic analysis of ADC drugs, determination of drug binding affinity, analysis of Drug Antibody Ratio (DAR), and evaluation of ADC drug efficacy.

Figure. 1 DXD-the most promising payload for next-generation ADCs ^[1]